Published Papers by IgAN Investigators

Efstathios Alexopoulos, MD
  1. Alexopoulos E, Seron D, Hartley RB, Nolasco F, Cameron JS. The role of interstitial infiltrates in IgA nephropathy: a study with monoclonal antibodies. Nephrol Dial Transplant. 1989;4(3):187-95.
  2. Alexopoulos E, Papaghianni A, Papadimitriou M. The pathogenetic significance of C5b-9 in IgA nephropathy. Nephrol Dial Transplant. 1995;10(7):1166-72.
  3. Alexopoulos E. Treatment of primary IgA nephropathy. Kidney Int. 2004 Jan;65(1):341-55.
  4. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen. Ren Fail. 2004 Jul;26(4):453-9.
  5. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frasca GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  6. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
Jurgen Flege, MD
  1. Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 1991 Sep;40(3):477-88.
  2. Yoshimura A, Gordon K, Alpers CE, Floege J, Pritzl P, Ross R, Couser WG, Bowen-Pope DF, Johnson RJ. Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney Int. 1991 Sep;40(3):470-6.
  3. Johnson R, Iida H, Yoshimura A, Floege J, Bowen-Pope DF. Platelet-derived growth factor: a potentially important cytokine in glomerular disease. Kidney Int. 1992 Mar;41(3):590-4.
  4. Johnson RJ, Floege J, Couser WG, Alpers CE. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol. 1993 Aug;4(2):119-28. Erratum in: J Am Soc Nephrol 1993 Nov;4(5):1237.
  5. Johnson RJ, Lombardi D, Eng E, Gordon K, Alpers CE, Pritzl P, Floege J, Young B, Pippin J, Couser WG, et al. Modulation of experimental mesangial proliferative nephritis by interferon-gamma. Kidney Int. 1995 Jan;47(1):62-9.
  6. Zwirner J, Burg M, Schulze M, Brunkhorst R, Gotze O, Koch KM, Floege J. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 1997 Apr;51(4):1257-64.
  7. Burg M, Ostendorf T, Mooney A, Koch KM, Floege J. Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety. Lab Invest. 1997 Apr;76(4):505-16.
  8. Ohmacht C, Kliem V, Burg M, Nashan B, Schlitt HJ, Brunkhorst R, Koch KM, Floege J. Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation. 1997 Nov 27;64(10):1493-6.
  9. Floege J, Burg M, Hugo C, Gordon KL, Van Goor H, Reidy M, Couser WG, Koch KM, Johnson RJ. Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 1998 May;9(5):792-801.
  10. Floege J, Burg M, Kliem V. Recurrent IgA nephropathy after kidney transplantation: not a benign condition. Nephrol Dial Transplant. 1998 Aug;13(8):1933-5.
  11. Floege J. New diagnostic and therapeutic aspects in IgA nephropathy. Kidney Blood Press Res. 1998;21(2-4):283-5.
  12. Floege J. The immunopathogenesis of IgA-nephropathy. Przegl Lek. 1998;55 Suppl 1:19-21.
  13. Floege J, Mertens P. Therapy of patients with IgA-nephropathy: a critical appraisal. Kidney Blood Press Res. 2000;23(3-5):207-9.
  14. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol. 2000 Dec;11(12):2395-403.
  15. Ostendorf T, Kunter U, Grone HJ, Bahlmann F, Kawachi H, Shimizu F, Koch KM, Janjic N, Floege J. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2001 May;12(5):909-18.
  16. Westenfeld R, Gawlik A, de Heer E, Kitahara M, Abou-Rebyeh F, Floege J, Ketteler M. Selective inhibition of inducible nitric oxide synthase enhances intraglomerular coagulation in chronic anti-Thy 1 nephritis. Kidney Int. 2002 Mar;61(3):834-8.
  17. Ostendorf T, Kunter U, van Roeyen C, Dooley S, Janjic N, Ruckman J, Eitner F, Floege J. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol. 2002 Mar;13(3):658-67.
  18. Gaertner SA, Janssen U, Ostendorf T, Koch KM, Floege J, Gwinner W. Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2002 Dec;13(12):2930-7.
  19. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant. 2003 Feb;18(2):241-5.
  20. Eitner F, Ostendorf T, Kretzler M, Cohen CD, Eriksson U, Grone HJ, Floege J; ERCB-Consortium. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol. 2003 May;14(5):1145-53.
  21. Janssen U, Eitner F, Kunter U, Ostendorf T, Wolf G, Chaponnier C, Gabbiani G, Kerjaschki D, Floege J. Extracellular actin impairs glomerular capillary repair in experimental mesangioproliferative glomerulonephritis. Nephron Exp Nephrol. 2003;93(4):e158-67.
  22. Mertens PR, Floege J. [IgA-nephropathy: the most common type of glomerulonephritis] Dtsch Med Wochenschr. 2003 May 30;128(22):1242-6.
  23. Kriz W, Hahnel B, Hosser H, Ostendorf T, Gaertner S, Kranzlin B, Gretz N, Shimizu F, Floege J. Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis. J Am Soc Nephrol. 2003 Jul;14(7):1904-26.
  24. Ostendorf T, van Roeyen CR, Peterson JD, Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J, Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ, Floege J. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2003 Sep;14(9):2237-47.
  25. Floege J, Eitner F, Van Roeyen C, Ostendorf T. PDGF-D and renal disease: yet another one of those growth factors? J Am Soc Nephrol. 2003 Oct;14(10):2690-1.
  26. Floege J, Grone HJ. [IgA nephropathy: frequent, but rarely diagnosed] Internist (Berl). 2003 Sep;44(9):1131-9.
  27. Steinmetz OM, Panzer U, Harendza S, Mertens PR, Ostendorf T, Floege J, Helmchen U, Stahl RA. No association of the -2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. Nephrol Dial Transplant. 2004 Mar;19(3):596-601.
  28. Floege J. Recurrent IgA nephropathy after renal transplantation. Semin Nephrol. 2004 May;24(3):287-91.
  29. Raffetseder U, Wernert N, Ostendorf T, van Roeyen C, Rauen T, Behrens P, Floege J, Mertens PR. Mesangial cell expression of proto-oncogene Ets-1 during progression of mesangioproliferative glomerulonephritis. Kidney Int. 2004 Aug;66(2):622-32.
  30. Panzer U, Schneider A, Steinmetz OM, Wenzel U, Barth P, Reinking R, Becker JU, Harendza S, Zahner G, Fischereder M, Kramer BK, Schlondorff D, Ostendorf T, Floege J, Helmchen U, Stahl RA. The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int. 2005 Jan;67(1):75-81. Erratum in: Kidney Int. 2005 Mar;67(3):1213.
  31. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005 Jun;16(6):1733-41.
  32. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005 Jun;67(6):2313-20.
  33. van Roeyen CR, Eitner F, Martinkus S, Thieltges SR, Ostendorf T, Bokemeyer D, Luscher B, Luscher-Firzlaff JM, Floege J, Mertens PR. Y-box protein 1 mediates PDGF-B effects in mesangioproliferative glomerular disease. J Am Soc Nephrol. 2005 Oct;16(10):2985-96.
  34. Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol. 2005 Jul-Aug;18(4):354-61.
  35. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frasca GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  36. Floege J. Is mycophenolate mofetil an effective treatment for persistent proteinuria in patients with IgA nephropathy? Nat Clin Pract Nephrol. 2006 Jan;2(1):16-7.
  37. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
  38. Ostendorf T, Rong S, Boor P, Wiedemann S, Kunter U, Haubold U, van Roeyen CR, Eitner F, Kawachi H, Starling G, Alvarez E, Smithson G, Floege J. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2006 Apr;17(4):1054-62.
  39. Beck S, Beck G, Ostendorf T, Floege J, Lambeau G, Nevalainen T, Radeke HH, Gurrieri S, Haas U, Thorwart B, Pfeilschifter J, Kaszkin M. Upregulation of group IB secreted phospholipase A(2) and its M-type receptor in rat ANTI-THY-1 glomerulonephritis. Kidney Int. 2006 Oct;70(7):1251-60.
Giovanni Maria Frasc, MD
  1. Vangelista A, Frasca GM, Mondini S, Bonomini V. Idiopathic IgA mesangial nephropathy: immunohistological features.Contrib Nephrol. 1984;40:167-73.
  2. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  3. Frasca GM, Soverini L, Gharavi AG, Lifton RP, Canova C, Preda P, Vangelista A, Stefoni S.Thin basement membrane disease in patients with familial IgA nephropathy. J Nephrol. 2004 Nov-Dec;17(6):778-85.
  4. Frasca GM, Onetti-Muda A, Mari F, Longo I, Scala E, Pescucci C, Roccatello D, Alpa M, Coppo R, Li Volti G, Feriozzi S, Bergesio F, Schena FP, Renieri A; Italian Renal Immunopathology Group. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant. 2005 Mar;20(3):545-51.
  5. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frasca GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
Gian Marco Ghiggeri, MD
  1. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  2. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frasca GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  3. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frasca G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006 May;47(5):761-9.
Francesco Paolo Schena, MD
  1. Schena FP, Mastrolitti G, Fracasso AR, Pastore A, Ladisa N. Increased immunoglobulin-secreting cells in the blood of patients with active idiopathic IgA nephropathy. Clin Nephrol. 1986 Oct;26(4):163-8.
  2. Schena PF, Pastore A, Sinico RA, Montinaro V, Fornasieri A. Polymeric IgA and IgA rheumatoid factor decrease the capacity of serum to solubilize circulating immune complexes in patients with primary IgA nephropathy. J Immunol. 1988 Jul 1;141(1):125-30.
  3. Schena FP, Pastore A, Montinaro V. The role of polymeric IgA in complement-mediated solubilization of IgG and IgA immune complexes. Am J Kidney Dis. 1988 Nov;12(5):433-6.
  4. Manno C, Stella M, Manno M, Fornarelli G, D'Agostino C, Quagliara D, Schena FP. Increased plasma levels of immunoreactive human atrial natriuretic factor in primary IgA nephropathy. Clin Nephrol. 1988 Dec;30(6):308-14.
  5. Antonaci S, Serlenga E, Garofalo AR, Colizzi M, Schena FP. Imbalance of T cell immunoregulatory subsets in primary IgA nephropathy. Cytobios. 1989;59(237):95-100.
  6. Schena FP, Mastrolitti G, Jirillo E, Munno I, Pellegrino N, Fracasso AR, Aventaggiato L. Increased production of interleukin-2 and IL-2 receptor in primary IgA nephropathy. Kidney Int. 1989 Mar;35(3):875-9.
  7. Schena FP, Pastore A, Ludovico N, Sinico RA, Benuzzi S, Montinaro V. Increased serum levels of IgA1-IgG immune complexes and anti-F(ab')2 antibodies in patients with primary IgA nephropathy. Clin Exp Immunol. 1989 Jul;77(1):15-20.
  8. Rifai A, Schena FP, Montinaro V, Mele M, D'Addabbo A, Nitti L, Pezzullo JC. Clearance kinetics and fate of macromolecular IgA in patients with IgA nephropathy Lab Invest. 1989 Oct;61(4):381-8.
  9. Schena FP, Montenegro M, Scivittaro V. Meta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease). Nephrol Dial Transplant. 1990
  10. Wyatt RJ, Rivas ML, Schena FP, Bin JA, Julian BA. Regional variation in C4 phenotype in patients with IgA nephropathy. J Pediatr. 1990 May;116(5):S72-7.
  11. Schena FP.A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990 Aug;89(2):209-15.
  12. Schena FP. [IgA nephropathy. A frequent disease in the Mediterranean area] Recenti Prog Med. 1991 Jun;82(6):338-43
  13. Antonaci S, Polignano A, Ottolenghi A, Tortorella C, Schena FP. Redistribution of natural killer (NK) cell frequency and NK cytotoxic activity in primary IgA nephropathy. Cytobios. 1992;69(276):27-34.
  14. Schena FP, Gesualdo L, Montinaro V. Immunopathological aspects of immunoglobulin A nephropathy and other mesangial proliferative glomerulonephritides. J Am Soc Nephrol. 1992 Apr;2(10 Suppl):S167-72.
  15. Schena FP, Scivittaro V, Ranieri E, Sinico R, Benuzzi S, Di Cillo M, Aventaggiato L. Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy. Clin Exp Immunol. 1993 Apr;92(1):139-44.
  16. Scivittaro V, Gesualdo L, Ranieri E, Marfella C, Schewn SA, Emancipator SN, Schena FP. Profiles of immunoregulatory cytokine production in vitro in patients with IgA nephropathy and their kindred. Clin Exp Immunol. 1994 May;96(2):311-6.
  17. Gesualdo L, Di Paolo S, Milani S, Pinzani M, Grappone C, Ranieri E, Pannarale G, Schena FP. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J Clin Invest. 1994 Jul;94(1):50-8.
  18. Scivittaro V, Ranieri E, Di Cillo M, Aventaggiato L, Emancipator SN, Schena FP. In vitro immunoglobulin production in relatives of patients with IgA nephropathy. Clin Nephrol. 1994 Jul;42(1):1-8.
  19. Ventura MT, Gesualdo L, Capobianco V, Tortorella C, Antonaci S, Schena FP. Effects of in vitro nutrient supplementation on polymorphonuclear cell respiratory burst in primary IgA nephropathy. Clin Nephrol. 1995 Jan;43(1):14-9.
  20. Schena FP. Immunogenetic aspects of primary IgA nephropathy. Kidney Int. 1995 Dec;48(6):1998-2013.
  21. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, Schena FP. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol. 1996 Jun;7(6):906-13.
  22. Ranieri E, Gesualdo L, Petrarulo F, Schena FP. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 1996 Dec;50(6):1990-2001.
  23. Montinaro V, Gesualdo L, Ranieri E, Monno R, Grandaliano G, Schena FP. Renal cortical complement C3 gene expression in IgA nephropathy. J Am Soc Nephrol. 1997 Mar;8(3):415-25.
  24. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant. 1997 Mar;12(3):418-26.
  25. Chen M, Schena FP, Wang SP, Grayston JT, Johnson RJ. Role of chlamydia pneumoniae (TWAR) in IgA nephropathy. Nephron. 1998 Sep;80(1):92.
  26. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  27. Schena FP. Immunoglobulin a nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists. Am J Med. 2001 Apr 15;110(6):499-500.
  28. Ranieri E, Gesualdo L, Grandaliano G, Maiorano E, Schena FP. The role of alpha-smooth muscle actin and platelet-derived growth factor-beta receptor in the progression of renal damage in human IgA nephropathy. J Nephrol. 2001 Jul-Aug;14(4):253-62.
  29. Manno C, Gesualdo L, D'Altri C, Rossini M, Grandaliano G, Schena FP. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy. J Nephrol. 2001 Jul-Aug;14(4):248-52.
  30. Schena FP, D'Altri C, Cerullo G, Manno C, Gesualdo L. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. Kidney Int. 2001 Aug;60(2):732-40.
  31. Schena FP, Cerullo G, Rossini M, Lanzilotta SG, D'Altri C, Manno C. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol. 2002 Feb;13(2):453-60.
  32. Schena FP. For further investigations in IgA nephropathy the approach from phenotype to genotype is welcome. Clin Exp Immunol. 2002 Mar;127(3):399-401.
  33. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2003;(4):CD003965.
  34. Strippoli GF, Manno C, Schena FP. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis. 2003 Jun;41(6):1129-39.
  35. Grandaliano G, Pontrelli P, Cerullo G, Monno R, Ranieri E, Ursi M, Loverre A, Gesualdo L, Schena FP. Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis. J Am Soc Nephrol. 2003 Aug;14(8):2072-83.
  36. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials.Nephrology (Carlton). 2004 Aug;9(4):177-85.
  37. Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP; Italian Immunopathology Group, Italian Society of Nephrology. The Italian experience of the national registry of renal biopsies. Kidney Int. 2004 Sep;66(3):890-4.
  38. Dal Canton A, Amore A, Barbano G, Coppo R, Emma F, Grandaliano G, Klersy C, Perfumo F, Rizzoni G, Schena FP, Sepe V; Angiotensin Inhibition Mycophenolate mophetil IgA Nephropathy study investigators. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. J Nephrol. 2005 Mar-Apr;18(2):136-40.
  39. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frasca GM; European IgA nephropathy Consortium. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  40. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
  41. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frasca G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006 May;47(5):761-9.
  42. Di Duca M, Oleggini R, Sanna-Cherchi S, Pasquali L, Di Donato A, Parodi S, Bertelli R, Caridi G, Frasca G, Cerullo G, Amoroso A, Schena FP, Scolari F, Ghiggeri GM. Cis and trans regulatory elements in NPHS2 promoter: Implications in proteinuria and progression of renal diseases. Kidney Int. 2006 Oct;70(7):1332-41.
Francesco Scolari, MD
  1. Scolari F, Amoroso A, Savoldi S, Prati E, Scaini P, Manganoni A, Borelli I, Mazzola G, Canale L, Sacchi G, et al. Familial occurrence of primary glomerulonephritis: evidence for a role of genetic factors. Nephrol Dial Transplant. 1992;7(7):587-96.
  2. Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, Viola BF, Nicola B, Movilli E, Sandrini M, Campanini M, Maiorca R. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. 1999 May;33(5):857-65.
  3. Scolari F. Familial IgA nephropathy. J Nephrol. 1999 Jul-Aug;12(4):213-9.
  4. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.
  5. Pirulli D, Boniotto M, Vatta L, Crovella S, Spano A, Morgutti M, Zezlina S, Bertola L, Roccatello D, Scolari F, Peruzzi L, Savoldi S, Amoroso A. Polymorphisms in the promoter region and at codon 54 of the MBL2 gene are not associated with IgA nephropathy. Nephrol Dial Transplant. 2001 Apr;16(4):759-64.
  6. Scolari F. Inherited forms of IgA nephropathy. J Nephrol. 2003 Mar-Apr;16(2):317-20.
  7. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frasca GM; European IgA nephropathy Consortium.The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol. 2005 Dec 5;6:14.
  8. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos E, Kirmizis D, Zelante L, Bisceglia L. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet. 2006 Apr;14(4):488-96.
  9. Izzi C, Sanna-Cherchi S, Prati E, Belleri R, Remedio A, Tardanico R, Foramitti M, Guerini S, Viola BF, Movilli E, Beerman I, Lifton R, Leone L, Gharavi A, Scolari F. Familial aggregation of primary glomerulonephritis in an Italian population isolate: Valtrompia study.Kidney Int. 2006 Mar;69(6):1033-40.
  10. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frasca G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006 May;47(5):761-9.